Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
Chin J Physiol ; 54(5): 318-23, 2011 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-22135910

RESUMO

Patients with type 1 diabetes are at a risk of hypertension. However, the mechanisms behind the findings are not completely known. The aim of the present study was to investigate involvement of interleukin-6 (IL-6) on the contraction of abdominal aorta in rats with type 1 diabetes. IL-6 levels in the plasma of rats with streptozotocin (STZ)-induced diabetes were determined by ELISA. The abdominal aorta was dissected free of fat and connective tissues and then cut into spiral rings. The endothelium-denuded strip was vertically suspended in tissue chambers containing 5 ml Krebs solution at 37 degrees C and bubbled continuously with 95% O2-5% CO2. The effects of phenylephrine (Phe) on the contractile responses of abdominal aorta were recorded. The effects of IL-6 and anti-rat IL-6 antibody on the Phe-induced response were also examined. Plasma levels of IL-6 increased time-dependently in rats with STZ-induced diabetes. Phe caused concentration-dependent contraction in aortic rings. Phe-induced contractions were higher in vascular strips of STZ-induced diabetic rats than that of control rats. Pretreatment of vascular strips with IL-6 for 1 h did not cause contraction but enhanced the contraction in response to Phe. Treatment of the vascular strips with an anti-IL-6 antibody for 1 h decreased the Phe-induced contractions. These results suggest that IL-6 causes vascular smooth muscle contraction in abdominal aorta of rats with type 1 diabetes.


Assuntos
Aorta Abdominal/fisiopatologia , Diabetes Mellitus Experimental/fisiopatologia , Interleucina-6/fisiologia , Músculo Liso Vascular/fisiopatologia , Vasoconstrição , Animais , Masculino , Músculo Liso Vascular/efeitos dos fármacos , Fenilefrina/farmacologia , Ratos , Ratos Wistar , Estreptozocina , Vasoconstrição/efeitos dos fármacos
2.
Int J Clin Exp Pathol ; 8(5): 4514-24, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26191141

RESUMO

Colonic dysmotility occurs in diabetes and blood plasma interleukin (IL)-6 levels are significantly elevated in type 1 diabetes mellitus. The aim of this study was to investigate whether IL-6 and the IL-6 receptor pathway mediates colonic dysfunction in type 1 diabetes mellitus. Male SD rats were treated with a single intraperitoneally injected dose of streptozotocin (STZ), and those displaying sustained high blood glucose were selected as diabetes mellitus models. Longitudinal muscle strips of colon were prepared to monitor colonic contraction in vitro. Contractile responses of strips of colon were recorded following treatment with IL-6 in control animals, and following anti IL-6 antibody treatment in STZ-induced diabetes in rats. Concentration of IL-6 in plasma and colon were determined by ELISA. Expressions of IL-6 α-receptor and IL-6 ß-receptor in colon tissues were determined by immunohistochemistry or Western blot analysis. The non-diabetes rats treated with IL-6 and the untreated diabetes rats showed increased contraction of distal colon, whereas the diabetes rats treated with anti-IL-6 antibody showed decreased contraction of distal colon compared with the untreated diabetes rats. The IL-6 levels of plasma but not colon increased in diabetes rats. The expression of IL-6 α-receptor increased in diabetes rats. These results indicate that diabetes rats show an increase in the contractions of distal colon partly via the IL-6-IL-6 receptor pathway.


Assuntos
Colo/efeitos dos fármacos , Receptor gp130 de Citocina/agonistas , Diabetes Mellitus Experimental/fisiopatologia , Diabetes Mellitus Tipo 1/fisiopatologia , Motilidade Gastrointestinal/efeitos dos fármacos , Subunidade alfa de Receptor de Interleucina-6/agonistas , Interleucina-6/farmacologia , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Animais , Carbacol/farmacologia , Colo/metabolismo , Colo/fisiopatologia , Receptor gp130 de Citocina/metabolismo , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Tipo 1/sangue , Relação Dose-Resposta a Droga , Técnicas In Vitro , Interleucina-6/sangue , Subunidade alfa de Receptor de Interleucina-6/metabolismo , Masculino , Músculo Liso/metabolismo , Músculo Liso/fisiopatologia , Ratos Sprague-Dawley , Transdução de Sinais/efeitos dos fármacos , Fatores de Tempo
3.
Cell Oncol (Dordr) ; 37(6): 429-37, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25404385

RESUMO

PURPOSE: The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, mediates a broad spectrum of biological processes, including ovarian growth and ovulation. Recently, we found that an endogenous AhR ligand (ITE) can inhibit ovarian cancer proliferation and migration via the AhR. Here, we tested whether 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, an exogenous AhR ligand) may exert similar anti-ovarian cancer activities using human ovarian cancer and non-cancerous human ovarian surface epithelial cells. METHODS: Two human ovarian cancer cell lines (SKOV-3 and OVCAR-3) and one human ovarian surface epithelial cell line (IOSE-385) were used. Cell proliferation and migration activities were determined using crystal violet and FluoroBlok insert system assays, respectively. AhR protein expression was assessed by Western blotting. Expression of cytochrome P450, family 1, member A1 (CYP1A1) and member B1 (CYP1B1) mRNA was assessed by qPCR. Small interfering RNAs (siRNAs) were used to knock down AhR expression. RESULTS: We found that TCDD dose-dependently suppressed OVCAR-3 cell proliferation, with a maximum effect (~70% reduction) at 100 nM. However, TCDD did not affect SKOV-3 and IOSE-385 cell proliferation and migration. The estimated IC50 of TCDD for inhibiting OVCAR-3 cell proliferation was 4.6 nM. At 10 nM, TCDD time-dependently decreased AhR protein levels, while it significantly increased CYP1A1 and CYP1B1 mRNA levels in SKOV-3, OVCAR-3 and IOSE-385 cells, indicating activation of AhR signaling. siRNA-mediated AhR knockdown readily blocked TCDD-mediated suppression of OVCAR-3 cell proliferation. CONCLUSION: Our data indicate that TCDD can suppress human ovarian cancer cell proliferation via the AhR signaling pathway and that TCDD exhibits an anti-proliferative activity in at least a subset of human ovarian cancer cells.


Assuntos
Neoplasias Ovarianas/metabolismo , Dibenzodioxinas Policloradas/farmacologia , Antineoplásicos , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Feminino , Humanos , Receptores de Hidrocarboneto Arílico/agonistas , Receptores de Hidrocarboneto Arílico/metabolismo
4.
Regul Pept ; 185: 29-33, 2013 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-23816471

RESUMO

Colonic dysmotility occurs in diabetes and the patients exhibit diarrhea or constipation. The pathogenetic mechanisms underlying colonic dysmotility in diabetic patients remain poorly understood. The effects of ß-arrestin2 on colonic contraction in diabetic rats were investigated for the first time. Male SD rats were treated with a single intraperitoneally injected dose of streptozotocin, and those displaying sustained high blood glucose were selected as diabetes mellitus models. Longitudinal muscle strips of the distal colon were prepared to monitor contraction of the colon in vitro. Expression of ß-arrestin2 was investigated by Western blot analysis. Anti-ß-arrestin2 antibody had no direct effect on the contraction of distal colonic strips in both normal and diabetic rats. Carbachol-induced contractions of distal colonic strips were higher in diabetic rats than in normal rats. Anti-ß-arrestin2 antibody partly blocked carbachol-induced increases of distal colonic strips in diabetic rats. The expression level of ß-arrestin2 protein in the colon was higher in diabetic rats than in normal rats. These results suggest that ß-arrestin2 is involved in the increase of distal colonic contraction in diabetic rats.


Assuntos
Arrestinas/fisiologia , Colo/fisiopatologia , Diabetes Mellitus Experimental/fisiopatologia , Músculo Liso/fisiopatologia , Animais , Arrestinas/farmacologia , Carbacol/farmacologia , Agonistas Colinérgicos/farmacologia , Colo/efeitos dos fármacos , Colo/metabolismo , Diabetes Mellitus Experimental/metabolismo , Técnicas In Vitro , Masculino , Contração Muscular , Músculo Liso/efeitos dos fármacos , Músculo Liso/metabolismo , Ratos , Ratos Sprague-Dawley , beta-Arrestinas
5.
Regul Pept ; 172(1-3): 30-4, 2011 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-21889546

RESUMO

Oxytocin (OT) has been reported to have a potential protective effect on stress-induced functional gastrointestinal disorders. This study determined whether colonic contraction in adults was affected by antenatal maternal hypoxia, and whether OT is involved in antenatal maternal hypoxia induced colonic contraction disorder. Isometric spontaneous contractions were recorded in colonic longitudinal muscle strips in order to investigate colonic contractions and the effects of exogenous OT on the contraction in antenatal maternal hypoxia and control mice. Both high potassium and carbachol-induced contractions of proximal colon but not distal colon were reduced in antenatal maternal hypoxia mice. Exogenous OT decreased the contractions of proximal colonic smooth muscle strips in control mice, while it increased contractions in antenatal maternal hypoxia mice. OT increased the contractions of distal colonic smooth muscle strips in both antenatal maternal hypoxia and control mice. Hexamethonium blocked the OT-induced potentiation of proximal colon but not distal colon in antenatal maternal hypoxia mice. These results suggest that exogenous oxytocin reverses the decrease of proximal colonic smooth muscle contraction in antenatal maternal hypoxia mice via ganglia.


Assuntos
Colo/efeitos dos fármacos , Colo/fisiologia , Gânglios/citologia , Hipóxia/fisiopatologia , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Ocitocina/farmacologia , Animais , Animais Recém-Nascidos , Colo/metabolismo , Feminino , Gânglios/efeitos dos fármacos , Gânglios/metabolismo , Motilidade Gastrointestinal/efeitos dos fármacos , Motilidade Gastrointestinal/fisiologia , Camundongos , Camundongos Endogâmicos BALB C , Músculo Liso/citologia , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA